
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
Hadeel Assad, MD, hematology/oncology fellow, Providence Hospital and Medical Center, discusses an analysis of the impact of breast cancer diagnosis on sexual dysfunction.
Hadeel Assad, MD, hematology/oncology fellow, Providence Hospital and Medical Center, discusses an analysis of the impact of breast cancer diagnosis on sexual dysfunction.
<<<






